NCT02031731View on ClinicalTrials.gov

The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 13, 2014

Primary Completion Date

April 14, 2014

Study Completion Date

April 14, 2014

Conditions
Neoplasms
Interventions
DRUG

4 mg/kg Onartuzumab (MetMAb)

4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.

DRUG

15 mg/kg Onartuzumab (MetMAb)

15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.

DRUG

30 mg/kg Onartuzumab (MetMAb)

30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.

Trial Locations (3)

100142

Beijing Cancer Hospital, Beijing

130021

the First Hospital of Jilin University, Changchun

510060

Sun Yet-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02031731 - The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter